Hematologic Oncology

Insights on how to approach an acute lymphocytic leukemia patient who is MRD positive after induction therapy.

Patricia Lugar, MD, MS, shares treatment algorithm and supportive care recommendations for a 75-year-old man with systemic mastocytosis.

Peter G. Miller, MD, PhD, discusses the characteristics of clonal hematopoiesis.

The panel of experts in SM discuss the diagnosis and management of a 75-year-old man with systemic mastocytosis.

A comprehensive breakdown of the tolerability of frontline targeted therapies used to manage chronic lymphocytic leukemia and toxicity management.

After determining the parameters of high-risk CLL, key opinion leaders clarify optimal frontline management strategies.

Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.

A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.

Krina K. Patel, MD, MSc, discusses the use of CAR T-cell therapy in multiple myeloma, potential target antigens beyond BCMA, the rich research landscape, and the role of quadruplets and radiation therapy.

This article discusses the current treatment landscape and therapeutic strategies for Waldenström macroglobulinemia, the role of Bruton tyrosine kinase inhibitor therapies in WM, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Duvelisib monotherapy demonstrated encouraging efficacy for patients with relapsed/refractory peripheral T-cell lymphoma.

The panel of experts comment on the optimal timing of hypomethylating agents and transplant in patients with high-risk myelodysplastic syndrome.

Zandelisib plus rituximab is being evaluated as a potentially chemotherapy-free treatment strategy vs standard chemoimmunotherapy in patients with indolent non-Hodgkin lymphoma in first relapse in the ongoing, phase 3 COASTAL trial.

The panel of experts highlight the risk factors and considerations for use of hypomethylating agents in patients with myelodysplastic syndrome versus acute myeloid leukemia.

Joshua F. Zeidner, MD, discusses the risk of transformation to acute myeloid leukemia in higher-risk myelodysplastic syndromes.

Zanubrutinib demonstrated clinical activity and tolerability in previously treated patients with B-cell malignancies who were intolerant to therapy with ibrutinib and/or acalabrutinib, according to results of the phase 2 BGB-3111-215 trial.

Expert hematologist-oncologists share insights into clinical trials studying how to best combine or sequence FLT3 and IDH inhibitors in patients with both mutations.

A panel of key opinion leaders in acute myeloid leukemia reflects on the importance of considering the toxicity profiles of IDH inhibitors and emphasizes the challenges of diagnosing differentiation syndrome.

Mikkael A. Sekeres, MD, explores prognostic and predictive factors inherent to high-risk MDS, including age and molecular abnormalities.

Yazan Madanat, MD, discusses available MDS risk assessment tools and provides insight into his preferred clinical assessment methods.

The combination of loncastuximab tesirine-lpyl and ibrutinib displayed encouraging antitumor activity with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.

Alison J. Moskowitz, MD, discusses recent developments made in the Hodgkin lymphoma paradigm, shared advice for optimal stratification, and spotlighted potential emerging prognostic markers that might further help to guide treatment decisions.

An overview of the treatment implications of testing for minimal residual disease in pediatric and AYA patients with ALL.

Drs Aldoss and McCloskey share their thoughts on treating patients with ALL at community centers versus at tertiary, academic medical centers.

Shared insight on clinical trial data for frontline targeted agents—specifically ibrutinib, acalabrutinib, and venetoclax—in chronic lymphocytic leukemia.